Simple Question: Haven't many/most small biotechs
Post# of 158219
 with a whole lot less evidence of efficacy, potential, and proven safety profile than Cytodyn?
 with a whole lot less evidence of efficacy, potential, and proven safety profile than Cytodyn?  If the science and MOA behind Leronlimab is solid - and from what the academic papers and those on our SAB vigorously and thoroughly confirm - then year after year, why do sit in the share price cellar?
The BP scientists aren't stupid, they know what our molecule can do and how much incredible $$$ potential it has, so what gives?
The only thing that makes sense to me is BP hoping to come up with their own miracle molecule so they don't need ours . . . and if they can't develop their own version of LL, if they string us along long enough until we run out of cash? Then all the better: they either get LL on the cheap or just bury it away.
At this point, with so much promise and potential, nothing else makes sense.
 (3)
(3) (1)
(1)
